Phaseline

Companies › Beijing Minhai Biotechnology

Beijing Minhai Biotechnology: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Vaccines.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PCV13-DT/TT
13-valent pneumococcal polysaccharide conjugate vaccine with diphtheria toxoid and tetanus
–Phase 3Pneumococcal Vaccines–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06608199PCV13-DT/TTPhase 3Pneumococcal VaccinesVaccinesJun 2025

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Medigen Vaccine Biologics Sinovac (Dalian) Vaccine Technology BioNet-Asia Aribio Lab Cellid

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.